Cost-effectiveness analysis of bicalutamide (Casodex) for adjuvant treatment of early prostate cancer.
Moeremans
Karen
K
Health Economics and Disease Management, Meise, Belgium.
Caekelbergh
Karin
K
Annemans
Lieven
L
D000368:Aged; D000813:Anilides / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008390:Markov Chains; D009362:Neoplasm Metastasis; D009570:Nitriles; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000191:economics* / Q000401:mortality; D013997:Time Factors; D014105:Tosyl Compounds
D000813:Anilides; D000970:Antineoplastic Agents; D009570:Nitriles; D014105:Tosyl Compounds; C053541:bicalutamide; D017430:Prostate-Specific Antigen